
|Videos|February 13, 2015
The Optimal Use of Cabazitaxel for Prostate Cancer
Author(s)Christopher Sweeney, MBBS
Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the optimal use of cabazitaxel for the treatment of prostate cancer.
Advertisement
Clinical Pearls
Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the optimal use of cabazitaxel for the treatment of prostate cancer.
- More oncologists are becoming comfortable with using the cytotoxic chemotherapy cabazitaxel. It is only approved for use after docetaxel.
- After prescribing docetaxel to a patient with hormone-sensitive disease, a physician can then choose to administer docetaxel again or switch to cabazitaxel.
- Sequencing of abiraterone, enzalutamide, cabazitaxel, docetaxel, sipuleucel-T, and radium-223 is not entirely clear.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5










































